No Detail Found!

Transthyretin: Molecular Functions, Immunological Roles and Its Involvement in Amyloidogenesis

Author(s)
Sama Attiyah Faculty of Immunology and Cardiology, University of Jeddah,,Saudi Arabia
Abstract
Transthyretin (TTR) is a homotetrameric transport protein primarily synthesized in the liver and choroid plexus. It serves as a carrier for thyroxine and retinol-binding protein but also exhibits broader biological functions, including neuroprotection and proteolytic activity. TTR also regulates myeloid cell development to regulate immune cell reaction. Structural destabilization of TTR can lead to its misfolding and aggregation into insoluble amyloid fibrils, resulting in transthyretin amyloidosis (ATTR), a group of systemic disorders characterized by extracellular amyloid deposition in multiple organs. Two major forms of ATTR have been described: hereditary (variant, ATTRv) and wild-type (ATTRwt) amyloidosis. ATTRwt arises from the aggregation of non-mutant TTR, primarily causing cardiomyopathy, whereas ATTRv results from pathogenic TTR gene mutations associated with neuropathic, cardiac or mixed phenotypes. Although current therapies can stabilize TTR tetramers or facilitate amyloid clearance, they primarily manage disease progression rather than achieve cure. This review aims to integrate current knowledge on the molecular structure and physiological functions of TTR, its immunomodulatory and cell-protective roles and its pathological involvement in amyloidogenesis. By highlighting the intersection between TTR's biological and immunological functions, the review underscores its relevance in understanding disease mechanisms and developing targeted therapeutic strategies.
Publication Details
Page(s) 97-106
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: 12, Year: 2025

Request the full text from PASTIC

Keywords
polyneuropathy, Transthyretin, Thyroxine, Amyloidogenesis
References
Liz M. . .A narrative review of the role of transthyretin in health and disease. ” Neurology and Therapy, 9(2020) : 395-402.
Sanguinetti C. .1906 .The journey of human transthyretin: Synthesis, structure stability and catabolism. ”Biomedicines, 10(2022) : .
Corino C. . .Tetrameric transthyretin as a protective factor against Alzheimer's disease. ” Molecular Neurobiology, 62(2025) : 2945-2954.
Ajmal M.R. . .Protein misfolding and aggregation in proteinopathies: Causes, mechanism and cellular response. ” Diseases, 11(2023) : 30.
Almeida Z.L.,R.M.M. Z.L. .2020 .Brito. “Structure and aggregation mechanisms in amyloids. ” Molecules, 25 : 1195.
Plantone D. .2023 .Current evidence supporting the role of immune response in ATTRv amyloidosis. ” Cells, 12(19) : 2383.
Faria T.Q. .2015 .A look into amyloid formation by transthyretin: Aggregation pathway and a novel kinetic model. ” Physical Chemistry Chemical Physics, 17(11) : 7255-7263.
Manso ,Marta .2017 .Senile systemic amyloidosis: An underdiagnosed disease. European Journal of Case Reports in Internal Medicine, 4(9) : 000725.
Manral N.,Reixach N. .2015 .Amyloidogenic and nonamyloidogenic transthyretin variants interact differently with human cardiomyocytes: Insights into early events of nonfibrillar tissue damage. ” Bioscience Reports, 35(6) : .
Guo X. .2020 .Review on the structures and activities of transthyretin amyloidogenesis inhibitors. ” Drug Design, Development and Therapy, 14 : 1057-1081.
Yokoyama T. .2012 .Hydrogen bond network and pH sensitivity in transthyretin: Neutron crystal structure of human transthyretin. ” Journal of Structural Biology, 177 : 283-290.
Zanotti G. .2017 .Structural and dynamics evidence for scaffold asymmetric flexibility of the human transthyretin tetramer. ” PLOS ONE, 0187716(12) : .
Richardson .2005 .Expression of transthyretin in the choroid plexus.” The Blood-Cerebrospinal Fluid Barrier. , : 279-307.
Habib C.,April C. .2022 .Umbilical cord and neonatal transthyretin and their relationship to growth and nutrition in preterm infants. ” Rambam Maimonides Medical Journal, 13(2) : .
Ingenbleek Y.,M. De Visscher Y. .1979 .Hormonal and nutritional status: Critical conditions for endemic goiter epidemiology?” Metabolism. , 28 : 9-19.
Aldred A.R. .1995 .The cerebral expression of plasma protein genes in different species. ” Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 111 : 1-15.
Pfeffer B.A. .2004 .Expression of transthyretin and retinolbinding protein mRNAs and secretion of transthyretin by cultured monkey retinal pigment epithelium. ” Molecular Vision, 10 : 23-30.
Jacobsson B. .1989 .Transthyretin immunoreactivity in human and porcine liver, choroid plexus and pancreatic islets. ” Journal of Histochemistry and Cytochemistry, 37 : 31-37.
Sousa M.M.,Saraiva M.J. .2001 .Internalization of transthyretin: Evidence of a novel yet unidentified receptorassociated protein (RAP)-sensitive receptor. ” Journal of Biological Chemistry, 276 : 14420-14425.
.2010 .Molecular aspects of thyroid hormone actions. ” Endocrine Reviews, 0007 : 139-170.
Palha J.A. .2002 .Thyroid hormone distribution in the mouse brain: The role of transthyretin. ” Neuroscience, 4522(02) : 00163-0.
Patel J. .2011 .Delivery of maternal thyroid hormones to the fetus. ” Trends in Endocrinology and Metabolism, 01 : 164-170.
Gudas L.J. “ .2011 .Emerging roles for retinoids in regeneration and differentiation in normal and disease states. ” Biochimica et Biophysica Acta, 10 : 213-221.
Shearer ,K.D. .2012 .A vitamin for the brain. ” Trends in Neurosciences, 08 : 733-741.
Lerner A.J. .2012 .Retinoids for treatment of Alzheimer's disease. ” Biofactors, 38 : 84-89.
Ono K. .2004 .Vitamin A exhibits potent anti amyloidogenic and fibril destabilizing effects in vitro. ” Experimental Neurology, 05 : 380-392.
Liu H.,MCB H. .2013 .Liver retinol transporter and receptor for serum retinol binding protein (RBP4). ” Molecular and Cellular Biology, 33(11) : 01408-12.
van Bennekum A.M. .2001 .Biochemical basis for depressed serum retinol levels in transthyretin deficient mice. ” Journal of Biological Chemistry, 276 : 1107-1113.
Sousa M.M. .2000 .Transthyretin in high density lipoproteins: Association with apolipoprotein A I.”. Journal of Lipid Research, 41 : 58-65.
Liz M. .2004 .Transthyretin, a new cryptic protease. ” Journal of Biological Chemistry, 279 : 21431-21438.
Liz M. .2007 .ApoA I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. ” Journal of Lipid Research, 48 : JLR200-2395.
Costa R. .2008 .Transthyretin protects against A β peptide toxicity by proteolytic cleavage of the peptide: A mechanism sensitive to the Kunitz protease inhibitor. ” PLOS ONE, 0002899 : .
Fleming C.E. .2007 .Transthyretin enhances nerve regeneration. ” Journal of Neurochemistry, 04864 : 4159-839.
Alshehri B. .2015 .The diversity of mechanisms influenced by transthyretin in neurobiology: Development, disease and endocrine disruption. ” Journal of Neuroendocrinology, 27 : 303-323.
Oliveira S.M. .2011 .Gender dependent transthyretin modulation of brain amyloid β levels: Evidence from a mouse model of Alzheimer's disease. ” Journal of Alzheimer's Disease, 22 : 405-412.
Thomas M.M. .2016 .Multimodality review of amyloid related diseases of the central nervous system. ” Radiographics, 36 : 1147-1163.
Alemi M. . .Transthyretin participates in beta amyloid transport from the brain to the liver-involvement of the low-density lipoprotein receptor related protein 1?” Scientific Reports. , 6(2016) : 20164.
Santos S.D. .2010 .CSF transthyretin neuroprotection in a mouse model of brain ischemia. ” Journal of Neurochemistry, 07080 : 4159-1444.
Gao C. .2011 .Serum prealbumin (transthyretin) predicts good outcomes in young patients with cerebral infarction. ” Clinical and Experimental Medicine, 11 : 49-54.
Vieira M. .1862 .Evidence for synergistic action of transthyretin and IGF-I over the IGF-I receptor. Biochimica et Biophysica Acta - Molecular Cell Research, (2016) : 797-804.
Chiu S.L. . .Insulin receptor signalling regulates synapse number, dendritic plasticity and circuit function in vivo. ” Neuron, 58(2008) : 708-719.
Zawislak A. .2017 .Neuron-derived transthyretin modulates astrocytic glycolysis in hormone-independent manner. ” Oncotarget, 8(63) : 106625-106638.
Laviola L. . .The IGF-I signalling pathway. ” Current Pharmaceutical Design, 13(2007) : 663-669.
Vieira M. . .Transthyretin induces insulin-like growth factor I nuclear translocation regulating its levels in the hippocampus. ” Molecular Neurobiology, 51(2015) : 1468-1479.
Rich L.R. .2019 .The role of brain glycogen in supporting physiological function. , 13 : 1176.
Lee C.C. . .Transthyretin stimulates tumor growth through regulation of tumor, immune and endothelial cells. ” Journal of Immunology, 202(2019) : 991-1002.
Li J. .2025 .Tissue-resident immune cells: From defining characteristics to roles in diseases. ” Signal Transduction and Targeted Therapy, 10 : 12.
Basha S. .2025 .Assessing amyloid fibrils and amorphous aggregates: A review. International Journal of Biological Macromolecules, 143725 : 143725.
Benson M.D. .2018 .Recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. ” Amyloid, 25(2018) : 215-219.
Coelho T. . .THAOS - The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. ” Current Medical Research and Opinion, 29(2013) : 63-76.
Beirão J.M. . .Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: A review of 513 cases. , 22(2015) : 117-122.
Solignac J. .2022 .Kidney involvement in hereditary transthyretin amyloidosis: A cohort study of 103 patients. Clinical Kidney Journal, 15 : 1747-1754.
Carroll A. . .Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. ” Journal of Neurology, Neurosurgery and Psychiatry, 93(2022) : 668-678.
Sekijima Y. . .The biological and chemical basis for tissue-selective amyloid disease. ” Cell, 121(2005) : 73-85.
Koike H. .2016 .Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. ” Neurology, 87(21) : 2220-2229.
Koike H.,Katsuno M. .2021 .The ultrastructure of tissue damage by amyloid fibrils. ” Molecules, 26(15) : 4611.
Rousseau A. .2018 .Angiographic signatures of the predominant form of familial transthyretin amyloidosis (Val30Met mutation). ” American Journal of Ophthalmology, 192 : 169-177.
Rapezzi C. .2009 .Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. ” Circulation, 120(13) : 1203-1212.
Benson M.D.,Kincaid J.C. . .The molecular biology and clinical features of amyloid neuropathy. ” Muscle and Nerve, 36(2007) : 411-423.
Schneider F. . .Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. ” Protein Science, 10(2001) : 1606-1613.
Koike H. .2009 .Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. ” Journal of the Neurological Sciences, 287(2) : 178-184.
Conceição I.,M. De Carvalho I. . .Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late- and early-onset cases in Portugal.” Muscle and Nerve. , 3(2007) : 116-118.
Pinto M.V. . .Neuromuscular amyloidosis: Unmasking the master of disguise. ” Muscle and Nerve, 64(2021) : 23-36.
N.R. .1997 .Intraepidermal nerve fibre density in patients with painful sensory neuropathy. ” Neurology, 48 : 708-711.
Ungerer M.N. . .Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: A 20-year German single-referral centre experience. ” Amyloid, 28(2021) : 91-99.
Duarte A.G. .2019 .Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: A systematic review. ” Clinical Autonomic Research, 29 : 1-9.
Lai ,M.K.L .2020 .A systematic review of developmental lumbar spinal stenosis. ” European Spine Journal, 29 : 2173-2187.
Çakar A. .2020 .Lumbar spinal stenosis: A rare presentation of hereditary transthyretin amyloidosis. NoroPsikiyatri Arsivi, 59 : 77-79.
Wininger A.E. .2021 .Musculoskeletal pathology as an early warning sign of systemic amyloidosis: A systematic review of amyloid deposition and orthopedic surgery. ” BMC Musculoskeletal Disorders, 22 : 51.
Yanagisawa A. .2015 .Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. ” Modern Pathology, 28 : 201-207.
Minnella A.M. . .Ocular involvement in hereditary amyloidosis. ” Genes, 12(2021) : 955.
Lessell S. .1975 .Scalloped pupils in familial amyloidosis. ” New England Journal of Medicine, 293 : 914-915.
Sousa L. .2021 .CNS involvement in hereditary transthyretin amyloidosis. ” Neurology, 97 : 1111-1119.
Brett M. .1999 .Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. ” Brain, 122 : 183-190.
Ellie E. . .Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). ” Neurology, 57(2001) : 135-137.
Jin K. .2004 .Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly representing repeated subarachnoid haemorrhages with superficial siderosis. ” Journal of Neurology, Neurosurgery and Psychiatry, 75 : 1463-1466.
Ruberg F.L. .2019 .Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. ” Journal of the American College of Cardiology, 73(22) : 2872-2891.
Yamamoto T.,Yokochi T. . .Transthyretin cardiac amyloidosis: An update on diagnosis and treatment. ” ESC Heart Failure, 6(2019) : 1128-1139.
Connors L.H. . .Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: A prospective, observational cohort study. ” Circulation, 133(2016) : 282-290.
Fenoglio R. .2022 .Renal involvement in transthyretin amyloidosis: The double presentation of transthyretin amyloidosis deposition disease. ” Nephron, 146 : 481-488.
Bordeneuve pp.V.,G. Said. pp.V. .2011 .Familial amyloid polyneuropathy.” The Lancet Neurology. , 10 : 1086-1097.
Ungericht M. .2023 .Amyloid myopathy: Expanding the clinical spectrum of transthyretin amyloidosis-Case report and literature review. ” Journal of Nuclear Cardiology, 30 : 1420-1426.
Almeida M.R. .2004 .Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 381 : 351-356.
Koike H.,Katsuno M. . .Ultrastructure in transthyretin amyloidosis: From pathophysiology to therapeutic insights. ” Biomedicines, 7(2019) : 11.
Berk J.L. .2013 .Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial. ” JAMA, 310 : 2658-2667.
Maurer M.S. .2018 .Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. ” New England Journal of Medicine, 379(11) : 1007-1016.
Obici L.,Adams D. .2020 .Acquired and inherited amyloidosis: Knowledge driving patients' care. ” Journal of the Peripheral Nervous System, 25 : 85-101.
Aimo A. .2022 .RNA-targeting and gene editing therapies for transthyretin amyloidosis. ” Nature Reviews Cardiology, 19(10) : 655-667.
Solomon S.D. . .Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. ” Circulation, 139(2019) : 431-443.
Vollmar J. .2018 .Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study. Transplant International, 31(11) : 1207-1215.
Sousa M. . .Heart transplantation in cardiac amyloidosis. ” Heart Failure Reviews, 22(2017) : 317-327.
0

Citations

0

Downloads

11

Views